Compass Therapeutics (NASDAQ:CMPX) Rating Increased to Outperform at Leerink Partners

Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a market perform rating to an outperform rating in a research note issued to investors on Wednesday morning, Marketbeat Ratings reports. They currently have $6.00 target price on the stock, up from their previous target price of $4.00.

Other research analysts also recently issued reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Tuesday. Guggenheim began coverage on Compass Therapeutics in a research report on Monday, February 24th. They set a “buy” rating and a $12.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Jefferies Financial Group raised their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. Finally, Piper Sandler assumed coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.63.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $1.69 on Wednesday. The stock has a market cap of $233.70 million, a PE ratio of -4.57 and a beta of 1.19. The stock’s fifty day moving average is $2.81 and its two-hundred day moving average is $2.11. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, research analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC purchased a new position in Compass Therapeutics during the 3rd quarter worth $30,000. Tower Research Capital LLC TRC raised its holdings in Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after purchasing an additional 12,917 shares in the last quarter. Independent Advisor Alliance acquired a new stake in Compass Therapeutics in the fourth quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics in the 4th quarter valued at approximately $27,000. Finally, XTX Topco Ltd acquired a new position in Compass Therapeutics during the 3rd quarter worth approximately $37,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.